ClinicalTrials.gg

Program

Pneumococcal 20-Valent Conjugate Vaccine

Also written as “20vPnC”, “20-valent pneumococcal conjugate vaccine” and “Prevnar 20”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Respiratory Syncytial Virus Infections, led by 4 companies.

Furthest: phase 3, since Nov 29, 201822 company-led studies, 5 open or runningNext primary completion: Jun 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer183 open or runningphase 3since Nov 29, 2018Nov 29, 2018Jun 10, 2027phase 1 · NCT07023081
GlaxoSmithKline20 open or runningphase 3since May 18, 2023Jun 3, 2022none ahead
LiteVax BV11 open or runningphase 1since Mar 30, 2025Mar 30, 2025none ahead
Merck11 open or runningphase 1since Dec 10, 2025Dec 10, 2025Oct 24, 2028phase 1 · NCT07300267

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 29, 2018.

  1. May 6, 20202 phase 3 studies in Pneumococcal InfectionsPfizer · NCT04379713, NCT04382326
  2. Aug 21, 20203 phase 3 studies in Pneumococcal InfectionsPfizer · NCT04546425, NCT04526574, NCT04530838
  3. Nov 18, 2020Phase 3 study in Pneumococcal InfectionsPfizer · NCT04642079 · 839 enrolled · United States
  4. May 3, 20212 phase 3 studies in Pneumococcal InfectionsPfizer · NCT04875533, NCT04887948
  5. Jun 1, 2022Phase 3 study in Pneumococcal InfectionsPfizer · NCT05408429 · 356 enrolled · Hungary, Poland, Spain
  6. Jun 3, 2022GlaxoSmithKline’s first study: phase 2 study in Pneumonia, BacterialNew to GlaxoSmithKlineGlaxoSmithKline · NCT05412030 · 388 enrolled · United States, Puerto Rico
  7. Aug 22, 2022Phase 3 study in Pneumococcal InfectionsPfizer · NCT05512819 · 541 enrolled · India, Taiwan
  8. May 16, 2023Phase 3 study in Pneumococcal InfectionsPfizer · NCT05875727 · 405 enrolled · India
  9. May 18, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT05879107 · 1,113 enrolled · United States, Belgium, Poland and more
  10. Mar 30, 2025LiteVax BV’s first study: phase 1 study in Vaccine ReactionNew to LiteVax BVLiteVax BV · NCT06986239 · 80 planned
  11. Jun 5, 20252 phase 1 studies in Pneumococcal InfectionsPfizer · NCT07019909, NCT07023081
  12. Aug 14, 2025Phase 3 study in HealthyPfizer · NCT07160244 · 6,000 planned · United States, Argentina, Brazil and more
  13. Dec 10, 2025Merck’s first study: phase 1 study in Pneumococcal InfectionsNew to MerckMerck · NCT07300267 · 210 planned · United States
  14. Jul 24, 2026Phase 3 study in Pneumococcal InfectionsPfizer · NCT07754539 · 1,250 planned · China

Ahead

  1. Jun 10, 2027Primary completion: phase 1 study in Pneumococcal InfectionsPfizer · NCT07023081
  2. Oct 24, 2028Primary completion: phase 1 study in Pneumococcal InfectionsMerck · NCT07300267
  3. Nov 6, 2028Primary completion: phase 3 study in HealthyPfizer · NCT07160244
  4. Nov 30, 2028Primary completion: phase 3 study in Pneumococcal InfectionsPfizer · NCT07754539

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 20 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 20-Valent Conjugate Vaccine”name, by rule

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07754539Pneumococcal Infections · China3RecruitingPfizerNov 30, 20281,250
NCT07300267Pneumococcal Infections · United States1RecruitingMerckOct 24, 2028210
NCT07160244Healthy · United States, Argentina, Brazil and more3RecruitingPfizerNov 6, 20286,000
NCT07023081Pneumococcal Infections · China1Active, not recruitingPfizerJun 10, 2027200
NCT07019909Pneumococcal Infections · China1CompletedPfizerJan 28, 2026400
NCT06986239Vaccine Reaction1Not yet recruitingLiteVax BVApr 1, 202680
NCT05879107Respiratory Syncytial Virus Infections · United States, Belgium, Poland and more3CompletedGlaxoSmithKlineDec 6, 20231,113
NCT05875727Pneumococcal Infections · India3CompletedPfizerOct 2, 2023405
NCT05512819Pneumococcal Infections · India, Taiwan3CompletedPfizerSep 20, 2025541
NCT05412030Pneumonia, Bacterial · United States, Puerto Rico2CompletedGlaxoSmithKlineSep 18, 2025388
NCT05408429Pneumococcal Infections · Hungary, Poland, Spain3CompletedPfizerJun 1, 2023356
NCT04887948Pneumococcal Infections · United States3CompletedPfizerDec 8, 2021570
NCT04875533Pneumococcal Infections · Japan, Korea, Republic of, Taiwan3CompletedPfizerMay 13, 20221,425
NCT04642079Pneumococcal Infections · United States3CompletedPfizerApr 6, 2022839
NCT04530838Pneumococcal Infections · Japan3CompletedPfizerApr 2, 2022668
NCT04546425Pneumococcal Infections · Australia, Belgium, Czechia and more3CompletedPfizerApr 22, 20221,258
NCT04526574Pneumococcal Infections · United States3CompletedPfizerJun 29, 20211,796
NCT04382326Pneumococcal Infections · United States, Puerto Rico3CompletedPfizerSep 2, 20221,997
NCT04379713Pneumococcal Infections · United States, Argentina, Canada and more3CompletedPfizerAug 31, 20221,511
NCT03835975Pneumococcal Infections · United States, Sweden3CompletedPfizerFeb 12, 2020875
NCT03828617Pneumococcal Infections · United States3CompletedPfizerOct 9, 20191,710
NCT03760146Pneumococcal Infections · United States, Sweden3CompletedPfizerDec 16, 20193,902

How it is read

Names in the registry

  • “20vPnC”, 10 entries
  • “20-valent pneumococcal conjugate vaccine”, 7 entries
  • “Prevnar 20”, 2 entries
  • “PCV20 (Stage 1)”, 1 entry
  • “PCV20 (Stage 2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.